In addition, some specific markers, such as using L-FABP to predict AKI in patients with underlying metabolic syndrome or non-alcoholic hepatic steatosis, and the use of NGAL in patients with sepsis, may be influenced by specific clinical situations. The gene discussed is LCN2; the disease is Hepatic steatosis.